Autoimmune polyglandular syndrome type 1 (APS1) is a rare, genetic autoimmune disorder that affects multiple endocrine glands. It is characterized by chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. The symptoms arise due to loss of function in specific glands such as parathyroid, adrenal and gonadal glands. APS1 requires lifelong management through hormone replacement and immunotherapy. The global APS1 market comprises products such as immunosuppressants, hormone replacement therapies, antifungal drugs, and vaccines. The market is driven by the increasing incidence of autoimmune disorders as a result of genetic and environmental factors. The Global Autoimmune Polyglandular Syndrome Type 1 Market is estimated to be valued at US$ 257.0 MN in 2024 and is expected to exhibit a CAGR of 3.1% over the forecast period 2024 to 2030.
Key players operating in the Global Autoimmune Polyglandular Syndrome Type 1 Market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S.
The key opportunities in the market include development of novel therapies targeting underlying autoimmunity and development of preventive vaccines. Geographically, North America dominates the market currently. However, Asia Pacific is expected to witness highest growth owing to improving healthcare infrastructure and increasingmedical expenses over the forecast period.
Europe is also expected to offer lucrative growth opportunities during the forecast period due to high incidence of APS1 and related autoimmune disorders. Moreover, growing awareness regarding early diagnosis and treatment adherence is driving the market globally.
Market Drivers and Restraints
The increasing incidence of autoimmune disorders due to rising environmental pollution and genetic predisposition are driving the APS1 market. Additionally, growing geriatric population who are more prone to developing autoimmune conditions acts as a growth driver. Also, increasing healthcare expenditures in developing nations and demand for effective drugs for long-term management of autoimmunity fuels the market growth.
However, lack of approved drugs for prevention and lack of understanding of precise etiology of APS1 are some of the major challenges in the market. Additionally, stringent regulatory framework for drugs approval acts as a market restraint. High treatment costs associated also impedes the market growth to some extent.
The Global Autoimmune Polyglandular Syndrome Type 1 Market can be segmented on the basis of disease type and end user. By disease type, Addison's disease dominates the market owing to high prevalence of this condition among Autoimmune Polyglandular Syndrome Type 1 patients. Addison's disease occurs when the body produces insufficient amounts of cortisol and aldosterone and is a life-threatening condition requiring timely management. By end user, hospitals hold a significant share due to availability of advanced treatment facilities and skilled healthcare professionals for taking care of such multi-system disorder patients. Outpatient care centers are expected to witness faster growth during the forecast period.
Regionally, North America is expected to account for the largest share in the global Autoimmune Polyglandular Syndrome Type 1 market due to high awareness levels, availability of advanced treatments and favorable reimbursement policies in countries like United States and Canada. Asia Pacific is anticipated to grow at the fastest rate during the forecast period driven by rapidly developing healthcare infrastructure, rising healthcare expenditure and increasing treatment seeking rate in developing countries like India and China. On the basis of treatments, immunosuppressive drug therapies hold the dominant market share as they help prevent the destruction of glands by autoimmune cells. But gene therapies are poised to offer lucrative opportunities in the coming years.
For more details on the report, Read- https://www.rapidwebwire.com/global-autoimmune-polyglandular-syndrome-type-1-market-growth/